Prednisone NDC 55154-2147

NDC codes

FDA NDC Directory

Product NDC (as listed)55154-2147Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55154-2147Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55154-2147-0	55154214700	10 BLISTER PACK in 1 BAG (55154-2147-0) / 1 TABLET in 1 BLISTER PACKMarketed from Jul 9, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prednisone
Generic name (nonproprietary): prednisone
Active ingredients: Prednisone — 20 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Cardinal Health 107, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040392
Marketing start: Jul 9, 2025
Marketing end: Mar 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 55154-2147_90b391d7-e8eb-4bde-b018-fb1878e7772bSPL ID 90b391d7-e8eb-4bde-b018-fb1878e7772bSPL set ID 199ed6a6-d9d9-49de-b383-5933a026591bRxCUI 312615, 312617UNII VB0R961HZTUPC 0055154214605
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N455154214700 followed by a unit qualifier and the quantity

Package 55154-2147-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 27, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE PredniSONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040392

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040392
Product	Strength	Form · route	Labeler	Product NDC
Prednisone	Prednisone 20 mg/1	TabletOral	Par Health USA, LLC	0603-5339
Prednisone	Prednisone 20 mg/1	TabletOral	American Health Packaging	60687-145